A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with <i>RET</i>-altered cancers.
Alexander Drilon(Memorial Sloan Kettering Cancer Center), Lori J. Wirth(Massachusetts General Hospital), Valentina Boni, Benjamin Besse(Institut Gustave Roussy), Keunchil Park(The University of Texas MD Anderson Cancer Center), Herbert H. Loong(Memorial Sloan Kettering Cancer Center), Jyoti D. Patel(Memorial Sloan Kettering Cancer Center), Manisha H. Shah(Pakistan Institute of Medical Sciences), Todd M. Bauer(Tennessee Oncology), Vivek Subbiah(Sarah Cannon), Martin Schlumberger(Université Paris-Saclay), Geoffrey R. Oxnard(Foundation Medicine (United States)), Benjamin Solomon(Peter MacCallum Cancer Centre), Melissa L. Johnson(Tennessee Oncology), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Vamsidhar Velcheti(Cleveland Clinic), Scott Cruickshank(Loxo Oncology at Lilly (United States)), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), S. Michael Rothenberg(Pfizer (United States))
Cited by 104
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k